Exagen Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 209

Employees

  • Stock Symbol
  • XGN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.49
  • (As of Thursday Closing)

Exagen General Information

Description

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Contact Information

Website
www.exagen.com
Formerly Known As
Exagen Diagnostics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1261 Liberty Way
  • Vista, CA 92081
  • United States
+1 (888)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences
Corporate Office
  • 1261 Liberty Way
  • Vista, CA 92081
  • United States
+1 (888)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exagen Stock Performance

As of 17-Apr-2025, Exagen’s stock price is $4.49. Its current market cap is $80.4M with 17.9M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.49 $4.47 $1.32 - $6.22 $80.4M 17.9M 132K -$0.83

Exagen Financials Summary

As of 31-Dec-2024, Exagen has a trailing 12-month revenue of $55.6M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 73,831 73,831 30,228 4,976
Revenue 55,641 55,641 52,548 45,563
EBITDA (11,656) (11,656) (20,081) (44,494)
Net Income (15,115) (15,115) (23,689) (47,387)
Total Assets 44,689 44,689 56,944 86,221
Total Debt 23,005 23,005 23,231 35,201
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Exagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis a
Laboratory Services (Healthcare)
Vista, CA
209 As of 2024

Aliso Viejo, CA
 

Sunnyvale, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exagen Competitors (21)

One of Exagen’s 21 competitors is Ambry Genetics, a Formerly PE-Backed company based in Aliso Viejo, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ambry Genetics Formerly PE-Backed Aliso Viejo, CA
CellMax Life Venture Capital-Backed Sunnyvale, CA
Biocept Formerly VC-backed San Diego, CA
Biodesix Formerly VC-backed Louisville, CO
Genova Diagnostics Private Equity-Backed Asheville, NC
You’re viewing 5 of 21 competitors. Get the full list »

Exagen Patents

  • 87

    Total Documents Applications and Grants

  • Total Patents Families

  • 33

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Exagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210220389-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Inactive 12-Aug-2019
US-20220299510-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019
CA-3150479-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019
EP-4013296-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Inactive 12-Aug-2019
EP-4013296-A4 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Inactive 12-Aug-2019 G01N33/6893
To view Exagen’s complete patent history, request access »

Exagen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Acquisitions (1)

Exagen’s most recent deal was a Merger/Acquisition with Cypress Bioscience (Diagnostic Business) for . The deal was made on 08-Oct-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cypress Bioscience (Diagnostic Business) 08-Oct-2010 Merger/Acquisition Biotechnology
To view Exagen’s complete acquisitions history, request access »

Exagen ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

23.52 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Healthcare

Industry

of 616

Rank

Percentile

Medical Services

Subindustry

of 114

Rank

Percentile

To view Exagen’s complete esg history, request access »

Exagen FAQs

  • When was Exagen founded?

    Exagen was founded in 2002.

  • Where is Exagen headquartered?

    Exagen is headquartered in Vista, CA.

  • What is the size of Exagen?

    Exagen has 209 total employees.

  • What industry is Exagen in?

    Exagen’s primary industry is Laboratory Services (Healthcare).

  • Is Exagen a private or public company?

    Exagen is a Public company.

  • What is Exagen’s stock symbol?

    The ticker symbol for Exagen is XGN.

  • What is the current stock price of Exagen?

    As of 17-Apr-2025 the stock price of Exagen is $4.49.

  • What is the current market cap of Exagen?

    The current market capitalization of Exagen is $80.4M.

  • What is Exagen’s current revenue?

    The trailing twelve month revenue for Exagen is $55.6M.

  • Who are Exagen’s competitors?

    Ambry Genetics, CellMax Life, Biocept, Biodesix, and Genova Diagnostics are some of the 21 competitors of Exagen.

  • What is Exagen’s annual earnings per share (EPS)?

    Exagen’s EPS for 12 months was -$0.83.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »